An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53-61.Dombret, H.; Gardin, C. An Update of Current Treatments for Adult Acute Myeloid Leukemia. Blood 2016, 127, 53-61.Dombret H,Gardin C.An update o f current treatments...
If one excludes acute promyelocytic leukemia, current AML management still relies largely on intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT), at least in younger patients who can tolerate such intensive treatments. Nevertheless, progress has been made, notably in terms...
g/m2twice a day for 3 days. Elderly and unfit patients received HMA (47%) as the preferred treatment.Conclusion: We showed that the most prevalent AML treatments were according to current guidelines. There is room to improve on the availability of diagnostic tools and the capacity to perform...
Treatment decisions for patients with chronic lymphocytic leukemia (CLL) are dependent on symptoms and classification into high-, medium-, or low-risk categories. The prognosis for CLL hinges, in part, on the presence or absence of less-favorable genetic aberrations, including del(17p), del(11q...
Novel therapies for multiple myeloma Multiple myeloma (MM) continues to evade cure by conventional therapies, increasing the urgency for new, biologically based treatments. Reviewed in this di... T Hayashi,T Hideshima,KC Anderson - 《British Journal of Haematology》...
Current treatment strategies in adult acute lymphoblastic leukemia This comprehensive overview on the most recent developments in treatments of adult acute lymphoblastic leukemia (ALL) discuss the controversies in the mana... X Thomas,Q Le - 《Bulletin Du Cancer》 被引量: 7发表: 2003年 The role ...
“These results will fully usher the treatment of chronic lymphocytic leukemia into a new era,” lead author Tait Shanafelt, MD, professor of medicine at Stanford, said in a statement. “We’ve found that this combination of targeted treatments is both more effective and less ...
Less than a third of adults with acute myeloid leukemia (AML) are cured by current treatments, emphasizing the need for new approaches to therapy. The disc... DS Krause,RAV Etten - 《Trends in Molecular Medicine》 被引量: 225发表: 2007年 The Effect of Imatinib Mesylate on Patients with ...
Current treatments seem effective only for a limited period of time. In addition, a significant proporti... S.,Galiegue-Zouitina,L.,... - 《Cancer Research》 被引量: 39发表: 2008年 Update on the Biology and Treatment Options for Hairy Cell Leukemia Hairy cell leukemia (HCL) is an ...
In the subgroup analysis, the PFS benefit was seen regardless of gender, tumor location, previous treatments (or treatment naïve), and in those with FAP syndrome. Forty-one percent of patients had an objec- tive response with nirogacestat compared to 8% with placebo (P < 0.001). ...